A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative intended ...

A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations traveled through the body and identified which part of the nervous system ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex’s long-running attempt to crack the blockbuster pain market has finally delivered a pair of phase 3 wins. And yet, the positive news was tempered by the failure to hit key secondary endpoints ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists. The ...

Explore the full archive of TIME, a century of journalism, insight, and perspective, with AI that helps you research, connect ...